DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study) : a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial
© 2023 The Author(s)..
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the urinary albumin-to-creatinine ratio (UACR) in patients with elevated levels of albuminuria in the presence or absence of heart failure (HF) or type 2 diabetes mellitus (T2D). However, these effects have not yet been reported in the presence of both HF and T2D. This lack of evidence prompted us to conduct a clinical trial on the effects of dapagliflozin on UACR in patients with HF and T2D.
Methods: DAPPER is a multicentre, randomised, open-labeled, parallel-group, standard treatment-controlled trial that enrolled patients at 18 medical facilities in Japan. Eligible participants with both HF and T2D and aged between 20 and 85 years were randomly assigned to a dapagliflozin or control (anti-diabetic drugs other than SGLT 2 inhibitors) group with a 1:1 allocation. The primary outcome was changes in UACR from baseline after a two-year observation, and secondary endpoints were cardiovascular (CV) events and parameters related to HF. This trial was registered with the UMIN-CTR registry, UMIN000025102 and the Japan Registry of Clinical Trials, jRCTs051180135.
Findings: Between 12 May 2017 and 31 March 2020, 294 patients were randomly assigned to the dapagliflozin group (n = 146) or control group (n = 148). The mean age of patients was 72.1 years and 29% were female. The mean glycated hemoglobin value was 6.9%, mean NT-proBNP was 429.1 pg/mL, mean estimated GFR was 65.7 mL/min/1.73 m2, and median UACR was 25.0 (8.8-74.6) mg/g Cr in the dapagliflozin group and 25.6 (8.2-95.0) mg/g Cr in the control group. Of the 146 patients in the dapagliflozin group, 122 completed the study, and 107 (87.7%) were taking 5 mg of dapagliflozin daily at the end of the observation period. The primary outcome did not significantly differ between the dapagliflozin and control groups. Among the secondary endpoints, the mean decrease in left ventricular end-diastolic dimensions as one of the echocardiographic parameters was larger in the dapagliflozin group than in the control group. The composite endpoint, defined as CV death or hospitalisation for CV events, hospitalisation for HF events, hospitalisation for all causes, and an additional change in prescriptions for heart failure in a two-year observation, was less frequent in the dapagliflozin group than in the control group.
Interpretation: Although dapagliflozin at a dose of 5 mg daily did not reduce urinary albumin excretion in patients with HF and T2D from that in the controls, our findings suggest that dapagliflozin decreased CV events and suppressed left ventricular remodeling.
Funding: AstraZeneca KK, Ono Pharmaceutical Co., Ltd.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
EClinicalMedicine - 66(2023) vom: 01. Dez., Seite 102334 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yoshihara, Fumiki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiovascular event |
|---|
| Anmerkungen: |
Date Revised 10.01.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.eclinm.2023.102334 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36683195X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36683195X | ||
| 003 | DE-627 | ||
| 005 | 20240114233550.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eclinm.2023.102334 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1255.xml |
| 035 | |a (DE-627)NLM36683195X | ||
| 035 | |a (NLM)38192595 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yoshihara, Fumiki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study) |b a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.01.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Author(s). | ||
| 520 | |a Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the urinary albumin-to-creatinine ratio (UACR) in patients with elevated levels of albuminuria in the presence or absence of heart failure (HF) or type 2 diabetes mellitus (T2D). However, these effects have not yet been reported in the presence of both HF and T2D. This lack of evidence prompted us to conduct a clinical trial on the effects of dapagliflozin on UACR in patients with HF and T2D | ||
| 520 | |a Methods: DAPPER is a multicentre, randomised, open-labeled, parallel-group, standard treatment-controlled trial that enrolled patients at 18 medical facilities in Japan. Eligible participants with both HF and T2D and aged between 20 and 85 years were randomly assigned to a dapagliflozin or control (anti-diabetic drugs other than SGLT 2 inhibitors) group with a 1:1 allocation. The primary outcome was changes in UACR from baseline after a two-year observation, and secondary endpoints were cardiovascular (CV) events and parameters related to HF. This trial was registered with the UMIN-CTR registry, UMIN000025102 and the Japan Registry of Clinical Trials, jRCTs051180135 | ||
| 520 | |a Findings: Between 12 May 2017 and 31 March 2020, 294 patients were randomly assigned to the dapagliflozin group (n = 146) or control group (n = 148). The mean age of patients was 72.1 years and 29% were female. The mean glycated hemoglobin value was 6.9%, mean NT-proBNP was 429.1 pg/mL, mean estimated GFR was 65.7 mL/min/1.73 m2, and median UACR was 25.0 (8.8-74.6) mg/g Cr in the dapagliflozin group and 25.6 (8.2-95.0) mg/g Cr in the control group. Of the 146 patients in the dapagliflozin group, 122 completed the study, and 107 (87.7%) were taking 5 mg of dapagliflozin daily at the end of the observation period. The primary outcome did not significantly differ between the dapagliflozin and control groups. Among the secondary endpoints, the mean decrease in left ventricular end-diastolic dimensions as one of the echocardiographic parameters was larger in the dapagliflozin group than in the control group. The composite endpoint, defined as CV death or hospitalisation for CV events, hospitalisation for HF events, hospitalisation for all causes, and an additional change in prescriptions for heart failure in a two-year observation, was less frequent in the dapagliflozin group than in the control group | ||
| 520 | |a Interpretation: Although dapagliflozin at a dose of 5 mg daily did not reduce urinary albumin excretion in patients with HF and T2D from that in the controls, our findings suggest that dapagliflozin decreased CV events and suppressed left ventricular remodeling | ||
| 520 | |a Funding: AstraZeneca KK, Ono Pharmaceutical Co., Ltd | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cardiovascular event | |
| 650 | 4 | |a Dapagliflozin | |
| 650 | 4 | |a Heart failure | |
| 650 | 4 | |a Sodium-glucose cotransporter 2 | |
| 650 | 4 | |a Type 2 diabetes mellitus | |
| 650 | 4 | |a Urinary albumin-to-creatinine ratio | |
| 700 | 1 | |a Imazu, Miki |e verfasserin |4 aut | |
| 700 | 1 | |a Sakuma, Ichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hiroi, Yukio |e verfasserin |4 aut | |
| 700 | 1 | |a Hara, Hisao |e verfasserin |4 aut | |
| 700 | 1 | |a Okazaki, Osamu |e verfasserin |4 aut | |
| 700 | 1 | |a Ishiguro, Chizuru |e verfasserin |4 aut | |
| 700 | 1 | |a Izumi, Chisato |e verfasserin |4 aut | |
| 700 | 1 | |a Noguchi, Teruo |e verfasserin |4 aut | |
| 700 | 1 | |a Shiraiwa, Toshihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Nishioka, Norio |e verfasserin |4 aut | |
| 700 | 1 | |a Fujii, Kenshi |e verfasserin |4 aut | |
| 700 | 1 | |a Iwakura, Katsuomi |e verfasserin |4 aut | |
| 700 | 1 | |a Tomonaga, Osamu |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Takihata, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yumoto, Kazuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Takase, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Himi, Toshiharu |e verfasserin |4 aut | |
| 700 | 1 | |a Shimizu, Ikki |e verfasserin |4 aut | |
| 700 | 1 | |a Murakami, Tsutomu |e verfasserin |4 aut | |
| 700 | 1 | |a Wagatsuma, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Katsuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Hiramatsu, Takeyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Akabame, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Hata, Shiro |e verfasserin |4 aut | |
| 700 | 1 | |a Asakura, Masanori |e verfasserin |4 aut | |
| 700 | 1 | |a Kawabata, Takanori |e verfasserin |4 aut | |
| 700 | 1 | |a Omae, Katsuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Shin |e verfasserin |4 aut | |
| 700 | 1 | |a Kitakaze, Masafumi |e verfasserin |4 aut | |
| 700 | 0 | |a DAPPER Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshihara, Fumiki |e investigator |4 oth | |
| 700 | 1 | |a Imazu, Miki |e investigator |4 oth | |
| 700 | 1 | |a Kawabata, Takanori |e investigator |4 oth | |
| 700 | 1 | |a Omae, Katsuhiro |e investigator |4 oth | |
| 700 | 1 | |a Izumi, Chisato |e investigator |4 oth | |
| 700 | 1 | |a Kanzaki, Hideaki |e investigator |4 oth | |
| 700 | 1 | |a Amaki, Makoto |e investigator |4 oth | |
| 700 | 1 | |a Okada, Atsushi |e investigator |4 oth | |
| 700 | 1 | |a Amano, Masashi |e investigator |4 oth | |
| 700 | 1 | |a Moriuchi, Kenji |e investigator |4 oth | |
| 700 | 1 | |a Ito, Shin |e investigator |4 oth | |
| 700 | 1 | |a Hosoda, Kiminori |e investigator |4 oth | |
| 700 | 1 | |a Makino, Hisashi |e investigator |4 oth | |
| 700 | 1 | |a Omura-Ohata, Yoko |e investigator |4 oth | |
| 700 | 1 | |a Tamanaha, Tamiko |e investigator |4 oth | |
| 700 | 1 | |a Koezuka, Ryo |e investigator |4 oth | |
| 700 | 1 | |a Noguchi, Michio |e investigator |4 oth | |
| 700 | 1 | |a Arisato, Tetsuya |e investigator |4 oth | |
| 700 | 1 | |a Noguchi, Teruo |e investigator |4 oth | |
| 700 | 1 | |a Tahara, Yoshio |e investigator |4 oth | |
| 700 | 1 | |a Kataoka, Yu |e investigator |4 oth | |
| 700 | 1 | |a Asaumi, Yasuhide |e investigator |4 oth | |
| 700 | 1 | |a Fujino, Masashi |e investigator |4 oth | |
| 700 | 1 | |a Otsuka, Fumiyuki |e investigator |4 oth | |
| 700 | 1 | |a Yoneda, Shuichi |e investigator |4 oth | |
| 700 | 1 | |a Honda, Satoshi |e investigator |4 oth | |
| 700 | 1 | |a Miura, Hiroyuki |e investigator |4 oth | |
| 700 | 1 | |a Sakuma, Ichiro |e investigator |4 oth | |
| 700 | 1 | |a Hiroi, Yukio |e investigator |4 oth | |
| 700 | 1 | |a Hara, Hisao |e investigator |4 oth | |
| 700 | 1 | |a Yamamoto, Masaya |e investigator |4 oth | |
| 700 | 1 | |a Okazaki, Toru |e investigator |4 oth | |
| 700 | 1 | |a Nakagawa, Takashi |e investigator |4 oth | |
| 700 | 1 | |a Kubota, Shuji |e investigator |4 oth | |
| 700 | 1 | |a Torii, Shunsuke |e investigator |4 oth | |
| 700 | 1 | |a Yamamoto, Jumpei |e investigator |4 oth | |
| 700 | 1 | |a Miyake, Wataru |e investigator |4 oth | |
| 700 | 1 | |a Nagai, Ran |e investigator |4 oth | |
| 700 | 1 | |a Ishiwata, Mai |e investigator |4 oth | |
| 700 | 1 | |a Okazaki, Osamu |e investigator |4 oth | |
| 700 | 1 | |a Ishiguro, Chizuru |e investigator |4 oth | |
| 700 | 1 | |a Shiraiwa, Toshihiko |e investigator |4 oth | |
| 700 | 1 | |a Nishioka, Norio |e investigator |4 oth | |
| 700 | 1 | |a Maeno, Yoshifumi |e investigator |4 oth | |
| 700 | 1 | |a Yamamoto, Kaoru |e investigator |4 oth | |
| 700 | 1 | |a Yoshida, Yoko |e investigator |4 oth | |
| 700 | 1 | |a Shiraiwa, Yuka |e investigator |4 oth | |
| 700 | 1 | |a Fujii, Kenshi |e investigator |4 oth | |
| 700 | 1 | |a Iwakura, Katsuomi |e investigator |4 oth | |
| 700 | 1 | |a Okamura, Atsunori |e investigator |4 oth | |
| 700 | 1 | |a Hirao, Yuko |e investigator |4 oth | |
| 700 | 1 | |a Tanaka, Koji |e investigator |4 oth | |
| 700 | 1 | |a Iwamoto, Mutsumi |e investigator |4 oth | |
| 700 | 1 | |a Tanaka, Nobuaki |e investigator |4 oth | |
| 700 | 1 | |a Okada, Masato |e investigator |4 oth | |
| 700 | 1 | |a Sumiyoshi, Akinori |e investigator |4 oth | |
| 700 | 1 | |a Tanaka, Kota |e investigator |4 oth | |
| 700 | 1 | |a Watanabe, Satoshi |e investigator |4 oth | |
| 700 | 1 | |a Harada, Shinichi |e investigator |4 oth | |
| 700 | 1 | |a Kashiyama, Toshikazu |e investigator |4 oth | |
| 700 | 1 | |a Tomonaga, Osamu |e investigator |4 oth | |
| 700 | 1 | |a Kobayashi, Koichi |e investigator |4 oth | |
| 700 | 1 | |a Ishiki, Ryoji |e investigator |4 oth | |
| 700 | 1 | |a Yamamoto, Dai |e investigator |4 oth | |
| 700 | 1 | |a Ito, Tadahiro |e investigator |4 oth | |
| 700 | 1 | |a Takihata, Masahiro |e investigator |4 oth | |
| 700 | 1 | |a Yumoto, Kazuhiko |e investigator |4 oth | |
| 700 | 1 | |a Fukuzawa, Tomoyuki |e investigator |4 oth | |
| 700 | 1 | |a Takase, Hiroyuki |e investigator |4 oth | |
| 700 | 1 | |a Hayashi, Kazusa |e investigator |4 oth | |
| 700 | 1 | |a Himi, Toshiharu |e investigator |4 oth | |
| 700 | 1 | |a Hyodo, Yusuke |e investigator |4 oth | |
| 700 | 1 | |a Ishibashi, Ryoichi |e investigator |4 oth | |
| 700 | 1 | |a Shimizu, Ikki |e investigator |4 oth | |
| 700 | 1 | |a Murakami, Tsutomu |e investigator |4 oth | |
| 700 | 1 | |a Ikari, Yuji |e investigator |4 oth | |
| 700 | 1 | |a Ohno, Yohei |e investigator |4 oth | |
| 700 | 1 | |a Sakama, Susumu |e investigator |4 oth | |
| 700 | 1 | |a Nakamura, Norihito |e investigator |4 oth | |
| 700 | 1 | |a Miyamoto, Junichi |e investigator |4 oth | |
| 700 | 1 | |a Torii, Sho |e investigator |4 oth | |
| 700 | 1 | |a Ijichi, Takeshi |e investigator |4 oth | |
| 700 | 1 | |a Lee, Kyong Hee |e investigator |4 oth | |
| 700 | 1 | |a Wagatsuma, Kenji |e investigator |4 oth | |
| 700 | 1 | |a Nii, Hideo |e investigator |4 oth | |
| 700 | 1 | |a Uchida, Yasuto |e investigator |4 oth | |
| 700 | 1 | |a Sato, Katsuhiko |e investigator |4 oth | |
| 700 | 1 | |a Hiramatsu, Takeyuki |e investigator |4 oth | |
| 700 | 1 | |a Takada, Yasunobu |e investigator |4 oth | |
| 700 | 1 | |a Akabame, Satoshi |e investigator |4 oth | |
| 700 | 1 | |a Koide, Masahiro |e investigator |4 oth | |
| 700 | 1 | |a Kitajima, Hiroki |e investigator |4 oth | |
| 700 | 1 | |a Kato, Yukinori |e investigator |4 oth | |
| 700 | 1 | |a Sogabe, Koji |e investigator |4 oth | |
| 700 | 1 | |a Fukui, Kento |e investigator |4 oth | |
| 700 | 1 | |a Kogure, Masaya |e investigator |4 oth | |
| 700 | 1 | |a Kishi, Akio |e investigator |4 oth | |
| 700 | 1 | |a Hata, Shiro |e investigator |4 oth | |
| 700 | 1 | |a Shinboku, Hiroki |e investigator |4 oth | |
| 700 | 1 | |a Muroya, Takahiro |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t EClinicalMedicine |d 2018 |g 66(2023) vom: 01. Dez., Seite 102334 |w (DE-627)NLM289300495 |x 2589-5370 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2023 |g day:01 |g month:12 |g pages:102334 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.eclinm.2023.102334 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2023 |b 01 |c 12 |h 102334 | ||